Data Integrity Remediation: A Practical Framework for Pharma

REPHINE SPEECH MARKS OPEN DIGITALISATION.png

Will Your Fixes Still Hold at the Next Inspection?

REPHINE SPEECH MARKS CLOSE DIGITALISATION.png

If your laboratory still treats a data integrity finding as a box to close rather than a control to sustain, you may be carrying more regulatory risk than you realise. A structured remediation plan is how you find out where that risk actually sits, and how you stop it coming back, before an inspector does.

In short

A data integrity remediation plan is a structured, risk based roadmap that turns audit and inspection findings into containment actions, corrective and preventive actions (CAPA) and sustainable governance, then verifies that those controls remain effective over time. Done well, it protects your laboratory data across its full lifecycle, from generation through to review, retention and long term oversight, not just until your next inspection.

About this Whitepaper

About This White Paper

If your laboratory has recently received a data integrity finding, you already understand the technical requirements. Your teams know ALCOA+, audit trail review and access control expectations. The harder question is what comes next.

This Rephine white paper sets out a practical framework for turning those requirements into a remediation plan that is realistic, risk based and sustainable in day to day operations, not just one that closes the findings from your last inspection. It walks you through seven phases, from defining scope to governing and sustaining your controls, so you can move from reactive remediation to a data integrity governance model you can apply directly to your own laboratory.

It is written for quality and laboratory leaders in pharmaceutical and life sciences organisations: QA and QC managers, computer system validation and IT teams, system owners and heads of quality who need their laboratory data to be complete, reliable and defensible.

What’s Changing?

Regulators are placing increasing pressure on organisations to demonstrate ongoing control over the entire data lifecycle, from generation and processing through to review, approval, retention and long term governance.

As a result, the goalposts are shifting. It is no longer enough to prove that controls once existed. You now need to demonstrate that those controls remain effective over time.

For most laboratories, the day to day picture is more complex than the paper record suggests. Legacy systems with known limitations sit alongside modern platforms. Manual data transcription is part of routine workflows. Critical data lives in shared folders, local databases and spreadsheets. Audit trail records exist but are not always complete, and responsibilities are not always clearly segregated. The shift in expectation is from a point in time proof of compliance to continuous, demonstrable control.

Why It Matters for Your Business

Your laboratory generates some of the most critical data in your quality system. Every batch release, out of specification investigation, stability study, environmental monitoring result and quality decision depends on that data being complete, reliable and defensible.

The business case for getting remediation right is straightforward:

  • Inspection readiness. A remediation plan that only closes today’s findings leaves you exposed at the next inspection. A sustainable framework helps you demonstrate continuous control.
  • Business continuity. Unmanaged critical and high risks can disrupt batch release and quality decisions. Containing them early protects your operations.
  • Efficient use of resources. A risk based approach focuses effort where your data is most exposed, rather than spreading it thinly across every finding.
  • Lasting confidence. When controls are owned and continuously challenged, the confidence in your data stays in your hands long after the project closes.

In the end, the quality of your data drives the quality of your decisions. And the quality of those decisions is what ultimately protects the patient.

Take Action Now

If you would like a clearer view of where your laboratory data is most exposed, the Rephine team can help you turn your findings into a realistic, risk based remediation roadmap that reflects the way your laboratory actually operates. Talk to Rephine Team about a data integrity assessment for your laboratory.

Download the full white paper below

Jul WP From Findings to Lasting Control

View our other resources and company news

ICH E6 Guide Header Image (1500 x 844 px) Case Study

From Cosmetics to OTC: Full FDA GMP Compliance Achieved in 12 Months

A global cosmetics manufacturer wanted to enter the OTC pharmaceutical market but had zero GMP experience. In 12 months, their Spanish production site achieved full ...
Read More
csv blog header jan 25 Article

GDP Transport Validation: A Practical Guide for Pharmaceutical Companies

Transport validation is a regulatory requirement under EU GMP Annex 15, yet many pharmaceutical companies still struggle with route selection and risk assessment. This guide ...
Read More
QMS IMP Header image case study May 25 Article

Veterinary GMP in Europe: New Dedicated Framework & VICH GL60 Guide

The EU veterinary sector enters a new era on 16 July 2026. Dedicated GMP regulations replace EudraLex Volume 4 for veterinary products. Learn what changes ...
Read More
mock inspection blog header Case Study

Full GMP Internal Audit Program Executed On Time

A pharmaceutical manufacturer needed to complete their annual EU GMP internal audit cycle across 11 departments, without the internal capacity to do it. See how ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan QMS

From local to global: scaling your QMS for UK–EU operations

Learn how UK life sciences companies can scale their quality management system into EU markets without losing compliance, visibility, or operational control.
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan QMS

Scale Your Quality System from UK to EU Without Losing Control

Learn how UK life sciences companies can scale their quality management system into EU markets without losing compliance, visibility, or operational control.
Read More
SAP PALEX CSV Case Study Header Image (1500 x 844 px) Article

Pharmaceutical Equipment Qualification & Control System Validation

Qualifying process equipment and control systems is fundamental to GMP compliance. This guide breaks down how to define user requirements, apply risk-based testing, and maintain ...
Read More
mock inspection blog header Case Study

GMP Consultancy for a New Cannabis Manufacturing Plant

A start up cannabis manufacturer partnered with Rephine to design a GMP compliant facility, implement a practical Quality Management System and prepare for EU GMP ...
Read More
QMS IMP Header image case study May 25 Article

How an Internal Services Audit Can Maximise Your Regulatory Compliance

Internal services audits play a critical role in maintaining GMP compliance and driving continuous improvement. This article explores how structured gap assessments, internal audits and ...
Read More
Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards